SenesTech, Inc. (Nasdaq: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control based in Flagstaff, Arizona began public trading on December 8, 2017. The initial public offering of 1,875,000 shares of common stock priced at $8.00 per share. In addition, SenesTech and certain selling stockholders have granted the underwriters a 30-day option to purchase up to 281,250 additional shares of common stock at the initial public offering price, less the underwriting discount. Continue reading
Author Archive: AZBio
arivis AG named to 2016 Red Herring Top 100 Global
MUNICH, Dec. 8, 2016 /PRNewswire/ — Red Herring announced that it has named arivis AG, a leader in 3D+ imaging and compliance software for the life, health and material sciences, to its Top 100 Global. This award recognizes leading private companies from North America, Europe, and Asia, celebrating their innovations and technologies across their respective industries.Continue reading
National Institutes of Health Bestows Grant to NeuroEM Therapeutics and Arizona State University for Collaborative Research in Alzheimer’s Disease
A Small Business Innovative Research (SBIR) grant has been awarded by the National Institutes of Health (NIH) to Phoenix-based NeuroEM Therapeutics, Inc. and Arizona State University. Continue reading
2016 AZBio Giving Guide
Looking to give back before year end? Check out the AZBio Annual Giving GuideContinue reading
TGen’s Dr. Von Hoff is named a ‘Giant of Cancer Care’
Honor recognizes the devotion of time, talent and resources to improving the care of cancer patients
US Food and Drug Administration awards Critical Path Institute 3 grants, 1 contract
The US Food and Drug Administration (FDA) has awarded Critical Path Institute (C-Path) three grants to develop data standards, as well as a contract to continue its research into drug-induced kidney injury. With these awards, the FDA continues to support C‑Path’s efforts to advance translational research toward accelerating drug development and regulatory review.Continue reading
Avery Therapeutics wins Get Started Tucson pitch competition
Avery Therapeutics, a company working toward commercializing a beating heart graft technology, won $60,000 in cash and services.Continue reading
NuvOx Pharma Awarded NIH Grant to Develop Technology to Increase Sensitivity and Specificity of Breast Cancer Diagnosis.
NuvOx Pharma, a Tucson based biotechnology company, has been awarded a grant from the National Cancer Institute for $298,820.00 entitled, “B7-H3-Targeted Contrast Agent for Ultrasonic Imaging of Breast Cancer”.Continue reading
Critical Path Iinstitute and CHDI Foundation, Inc. Establish a Consortium to Expedite Approval of Huntington’s Disease Therapeutics
Critical Path Institute (C-Path) and CHDI Foundation, Inc. (CHDI), are collaborating to set up a broad-based consortium that will more clearly define regulatory pathways leading to the approval of Huntington’s disease (HD) therapeutics.Continue reading
Scott Hathcock Named CEO of NACET
Scott Hathcock has worked for two years at the Chamber as vice president of business development and brings a strong entrepreneurial track record to the NACET Team.Continue reading